Skip to content

Testing the stability of a blood test for detecting early signs of Alzheimer's disease

Elecsys® Phospho-Tau (217P) Plasma Short Term Sample Stability Study in Multiple Matrices - Elecsys® Phospho-Tau (217P) Plasma Short Term Sample Stability Study in Multiple Matrices

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON58012
Enrollment
25
Registered
2025-06-06
Start date
2025-11-11
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s disease Alzheimer’s disease

Interventions

Elecsys® Phospho-Tau (217P) Plasma Assay

Sponsors

Roche Diagnostics International Ltd
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male or Female from 50 to 89 years old (inclusive) with cognitive concerns or with confirmed AD who are mentally competent (participants must be able to give the informed consent by themselves)

Exclusion criteria

Exclusion criteria: •Any woman who is pregnant or breastfeeding • The participant has received or is receiving any investigational treatment within 5 half-lives or 6 months (whichever is longer) prior to sample collection • Any participant who is receiving any anti-amyloid treatment • Any participant who is placed in an institution by court or official order or under supervision of a legal guardian • Contraindication** for donation of 45mL whole blood as judged by the investigator. **Contraindication criteria for the blood donation are e.g. (but not limited to) severe skin conditions, swelling or edema at puncture site, lymphedema, severe blood clotting disorders, anemia (haemoglobin concentration of < 12 g/dl for women and < 13 g/dl for men), acute inflammation at the injection site, allergies to disinfectants or other materials used in this context (latex, plasters).

Design outcomes

Primary

MeasureTime frame
Endpoints Stability Condition 25°C Acceptable temperature range 23°C to 27°C Target stability claim 2 days Stability measured in study 3 daysStability Condition 2-8 °C Acceptable temperature range 2-8 °C Target stability claim 7 days Stability measured in study 8 days Stability Condition -20°C Acceptable temperature range -20 °C (± 5 °C) Target stability claim 12 weeks Stability measured in study 13 weeks Stability Condition Freeze / Thaw (- 20°C/ 20 °C) Acceptable temperature range -20 °C (± 5 °C)/ 15°C to 25°C Target stability claim 1 cycle Stability measured in study 1 cycle  

Countries

Netherlands

Contacts

Public ContactNMJ Miljanovic Jovanovic

Roche Diagnostics International Ltd

nina.miljanovic_jovanovic@contractors.roche.com+49 171 1040 262

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 11, 2026